SCP Investment’s Clovis Oncology, Inc. CLVS Stock Holding History

SCP Investment’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-7,000	Closed	-$370K	–	74
2018 Q1	$370K	Buy	+7,000	New	+$408K	0.24%	47

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

SCP Investment's CLVS Position: Q2 2018 in Review

SCP Investment sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 7,000 shares — an estimated $370K sold.

SCP Investment first reported a position in CLVS in Q1 2018 and held it in 1 quarter. The position peaked at $370K in Q1 2018. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

SCP Investment reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
SCP Investment sold 7,000 Clovis Oncology, Inc. shares in Q2 2018, an estimated $370K.
SCP Investment first reported a position in Clovis Oncology, Inc. in Q1 2018 and held it in 1 quarter.
SCP Investment's Clovis Oncology, Inc. position peaked at $370K in Q1 2018.
210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on SCP Investment's 13F filing for Q2 2018, filed 15 Aug 2018.